VideoElephant logo x

AbbVie May Not Get All of Allergan for Antitrust Reasons, Argus Analyst Toung Says

  • Category business
  • Definition HD
  • Resolution 1280 x 720
  • Duration 00:02:41
  • Year 2019
  • Language English

AbbVie May Not Get All of Allergan for Antitrust Reasons, Argus Analyst Toung Says

Jun.25 -- David Toung, analyst at Argus Research, discusses AbbVie's $63 billion deal for Allergan on "Bloomberg Markets."

Interested in this content?